Agreement between WHO-UMC causality scale and the Naranjo algorithm for causality assessment of adverse drug reactions

被引:58
作者
Shukla, Ajay K. [1 ]
Jhaj, Ratinder [1 ]
Misra, Saurav [1 ]
Ahmed, Shah N. [2 ]
Nanda, Malaya [1 ]
Chaudhary, Deepa [3 ]
机构
[1] AIIMS Bhopal, Dept Pharmacol, Bhopal, Madhya Pradesh, India
[2] Coll Med & JNM Hosp, Dept Pharmacol, Kalyani, W Bengal, India
[3] AIIMS Bhopal, Dept ADR Monitoring Ctr AMC, Bhopal, Madhya Pradesh, India
关键词
Agreement between scales; causality assessment; Naranjo algorithm; WHO-UMC scale; PROBABILITY; CRITERIA; EVENTS;
D O I
10.4103/jfmpc.jfmpc_831_21
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: The Pharmacovigilance Program of India recommends the use of the World Health Organization-Uppsala Monitoring Centre (WHO-UMC) scale, while many clinicians prefer the Naranjo algorithm for its simplicity. In the present study, we assessed agreement between the two widely used causality assessment scales, that is, the WHO-UMC criteria and the Naranjo algorithm. Materials and Methods: In this study, 842 individual case safety reports were randomly selected from 1000 spontaneously reported forms submitted to the ADR Monitoring Center at a tertiary healthcare Institute in Central India between 2016 and 2018. Two well-trained independent groups performed the causality assessment. One group performed a causality assessment of the 842 ADRs using the WHO-UMC criteria and the other group performed the same using the Naranjo algorithm. The agreement between two ADR causality scales was assessed using the weighted kappa (kappa) test. Results: Cohen's kappa coefficient (kappa) statistical test was applied between the two scales (WHO-UMC scale and Naranjo algorithm) to find out the agreement between these two scales. "No" agreement was found between the two scales {Kappa statistic with 95% confidence interval = 0.048 (P < 0.001)}. Conclusion: There was no agreement found between the WHO-UMC criteria and the Naranjo algorithm in our study.
引用
收藏
页码:3303 / 3308
页数:6
相关论文
共 22 条
[1]  
Acharya T. A., 2020, BIOMED PHARMACOL J, V13, P79, DOI DOI 10.13005/bpj/1863
[2]   Methods for causality assessment of adverse drug reactions - A systematic review [J].
Agbabiaka, Taofikat B. ;
Savovic, Jelena ;
Ernst, Edzard .
DRUG SAFETY, 2008, 31 (01) :21-37
[3]   Factors affecting the development of adverse drug reactions (Review article) [J].
Alomar, Muaed Jamal .
SAUDI PHARMACEUTICAL JOURNAL, 2014, 22 (02) :83-94
[4]  
[Anonymous], 2012, LiverTox: Clinical and Research Information on Drug-Induced Liver Injury
[5]  
[Anonymous], 2002, Safety of Medicines: A Guide to Detecting and Reporting Adverse Drug Reactions: Why Health Professionals Need to Take Action
[6]   Comparison of different methods for causality assessment of adverse drug reactions [J].
Behera, Sapan Kumar ;
Das, Saibal ;
Xavier, Alphienes Stanley ;
Velupula, Srinivas ;
Sandhiya, Selvarajan .
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2018, 40 (04) :903-910
[7]   A study of agreement between the Naranjo algorithm and WHO-UMC criteria for causality assessment of adverse drug reactions [J].
Belhekar, Mahesh N. ;
Taur, Santosh R. ;
Munshi, Renuka P. .
INDIAN JOURNAL OF PHARMACOLOGY, 2014, 46 (01) :117-120
[8]   Sample-size calculations for Cohen's kappa [J].
Cantor, AB .
PSYCHOLOGICAL METHODS, 1996, 1 (02) :150-153
[9]  
Goyal R., 2019, Int Res J Pharm, V10, P195, DOI [10.7897/2230-8407.1003104, DOI 10.7897/2230-8407.1003104]
[10]  
송명균, 2008, [The Korean Journal of Medicine, 대한내과학회지], V74, P181